Skip to content

DBV Technologies DBVT Other intangible assets—net

Other intangible assets—net at other companies

Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$27.19M0.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.29B+10.3%

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$923.31M+269%
Enterprise value$700.21M+188%
P/S159.6×+89.0×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Debt / equity-2.5×
Current ratio4.8×+4.0×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's other intangible assets—net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's other intangible assets—net?
DBV Technologies (DBVT) reported other intangible assets—net of $100K in Q1 2026.
How has DBV Technologies's other intangible assets—net changed year-over-year?
DBV Technologies's other intangible assets—net increased by 244.8% year-over-year, from $29K to $100K.
What is the long-term trend for DBV Technologies's other intangible assets—net?
Over 5 years (2020 to 2025), DBV Technologies's other intangible assets—net has grown at a -100.0% compound annual growth rate (CAGR), from $41K to $0.
What does other intangible assets—net mean?
This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.